MedTrace Logo

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 960

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

Conditions

Interventions

DRUG

BMS-986365

Specified dose on specified days

DRUG

Enzalutamide

Specified dose on specified days

DRUG

Abiraterone

Specified dose on specified days

DRUG

Docetaxel

Specified dose on specified days

DRUG

Predinsone/Prednisolone

Specified dose on specified days

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-13
Primary Completion
2027-09-12
Completion
2029-01-19
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Brazil
  • Canada
  • Chile
  • China
  • Czechia
  • Denmark
  • France
  • Germany
  • India
  • Ireland
  • Italy
  • Japan
  • Poland
  • Puerto Rico
  • Romania
  • Slovakia
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06764485 on ClinicalTrials.gov